EUVIMEDSkopri EUVIMED
Leserbrief

Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection

Guan-Kai Lai iD, Chia-Yu Chu iD, Yung-Tsu Cho iD

Experimental Dermatology · 2026-05 · 35 (5)

DOI: 10.1111/exd.70257 ↗

At a glance

Leserbrief in Experimental Dermatology, published online on 2026-04-29. Written by Guan-Kai Lai and 2 co-authors. Institution: School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. 5 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Subjects

Author keywords

COVID‐19baricitinibdermatomyositistranscriptional intermediary factor 1

Authors and institutions

  • School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

ORCID profiles: Guan-Kai Lai, Chia-Yu Chu, Yung-Tsu Cho

Cite

APA

Lai, G. K., Chu, C. Y., & Cho, Y. T. (2026). Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection. Experimental Dermatology, 35(5). https://doi.org/10.1111/exd.70257

Vancouver

Lai GK, Chu CY, Cho YT. Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection. Experimental Dermatology. 2026;35(5). doi:10.1111/exd.70257

BibTeX
@article{Lai2026,
  author = {Lai, Guan-Kai and Chu, Chia-Yu and Cho, Yung-Tsu},
  title = {Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection},
  journal = {Experimental Dermatology},
  year = {2026},
  volume = {35},
  number = {5},
  doi = {10.1111/exd.70257}
}
Start for free →